Please login to the form below

Not currently logged in
Email:
Password:

Catalent appoints two board members

Jack Stahl and Rolf Classon to advise drug development, delivery and supply company
catalent-rolf-classon

Catalent has named two experienced healthcare figures to its board of directors.

Jack Stahl, former CEO of cosmetics firms Revlon, and Rolf Classon, former chairman at Bayer Healthcare, will use to their experience to advise Catalent, a leading player in providing drug development, delivery and supply services to pharma companies.

Stahl headed Revlon from 2002 to 2006 following a stint as chief operating officer at the Coca-Cola Company. He also serves on the Boards of Coty, Delhaize Group, and the US board of advisers of CVC Capital.

Classon served as chairman at Bayer Healthcare from 2002 until 2004 as part of a long career at Bayer that began in 1991. His roles at the German company included a seven-year spell as president of Bayer Diagnostics.

“We welcome both Jack and Rolf to our Board,” said John Chiminski, President and CEO, Catalent. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector.”

20th August 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics